Dr Reddy’s Laboratories

US FDA finds “significant violations” at India’s Strides plant

Read more

US FDA issues 5 observations to Dr Reddy’s plant in Hyderabad

Read more

Dr Reddys launches anti-phlegm OTC drug in US market

Read more

Dr Reddy’s Laboratories plans to launch value-added drugs in US

Read more

Budget reactions 2019

Read more

Dr Reddy’s launches generic Hemabate injection in US market

Read more

Dr Reddy’s launches in Phytonadione Injectable Emulsion USP in US market

Read more

DRL launches Cefixime for oral suspension

Read more

Dr Reddy’s to acquire Teva’s product portfolio for US Market

Read more

DRL enters branded consumer health arena through acquisition of six OTC brands

Read more